pharmacy-biopharma-2017-posters-accepted-abstracts

3 / 25

Page 50
Notes:
conferenceseries.com
Volume 9, Issue 5 (Suppl) J Bioequiv Availab, an open access journal
ISSN: 0975-0851 Pharmacy & Biopharma 2017
August 31-September 01, 2017 Philadelphia, USA
August 31-September 01, 2017 Philadelphia, USA
3rd International Conference on
Biopharmaceutics and Biologic Drugs
&
5th International Pharmacy Conference
Evaluation of keytruda for metastatic non-small cell lung cancer
Dewilka Simons
Temple University School of Pharmacy, USA
Keytruda (Pembrolizumab) is the only anti-PD-1 treatment approved for first-line combination with pemetrexed and
carboplatin and/or as monotherapy for the treatment of metastatic non-small cell lung cancer (mNSCLC) in appropriate
patients. Lung cancer is the second most common form of cancer in both men and women and NSCLC accounts for 80%- 85%
of all lung cancers. The 5-year survival rate for metastatic lung cancer is <18.1%. Cancer immunotherapy works by enhancing
or allowing the immune system to recognize and destroy cancer cells. Clinical responses targeting the programmed cell
death-1 (PD-1) pathway have shown promise in improving survival while maintaining a relatively tolerable toxicity profile.
Combination therapy with pemetrexed and carboplatin received accelerated approval based on tumor response rate and
progression-free survival in clinical trials. In combination therapy, the use of Keytruda is irrespective of PD-L1 status. The use
of Keytruda in the first-line monotherapy setting requires to have high expressions of PD-L1 with a tumor proportion score
(TPS) ≥50% in which the TPS must be determined by an FDA-approved test. The monotherapy indication received approval
based on overall survival and progression-free survival data in clinical trials.
Biography
Dewilka Simons is currently a third-year Pharmacy student at Temple University School of Pharmacy in Philadelphia. She has received her BS in Life Science
from the Pennsylvania State University in 2014 with an emphasis in cultural studies. Her interests are transplant therapy, critical care and infectious disease in
immunocompromised patients and patient education. She is the Vice President of the Interdisciplinary Health Advocacy (IDHA) a student run organization that
promotes interprofessional patient outreach. She hopes to pursue PGY-1 and PGY-2 residency in solid organ transplant upon graduation.
Dewilka Simons, J Bioequiv Availab 2017, 9:5 (Suppl)
DOI: 10.4172/0975-0851-C1-031